The Evaluation Committee has prepared a Final Evaluation Determination (FED) on eliglustat for treating type 1 Gaucher disease and submitted it to the Institute.
The FED has been sent to consultees for this evaluation who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors. The FED has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FED may be used as the basis for the Institute's guidance on the use of the evaluated highly specialised technology in the NHS in England.
Please note that the appeal period for this evaluation will close at 5pm on Wednesday 14 June 2017.
This page was last updated: